H&F weighs $9 billion-plus sale of medical device maker Cordis, Bloomberg News reports

Reuters01-17

UPDATE 2-H&F weighs $9 billion-plus sale of medical device maker Cordis, Bloomberg News reports

Updates with KKR comments in the last paragraph

Jan 16 (Reuters) - U.S. private equity firm Hellman & Friedman is in early-stage talks for a potential sale of medical devices maker Cordis, seeking a value of over $9 billion, Bloomberg News reported on Friday, citing people familiar with the matter.

About half a dozen publicly traded medical device companies are currently evaluating potential bids for Cordis, the report added.

Hellman & Friedman bought Cordis from Cardinal Health in 2021 for about $1 billion, six years after Johnson & Johnson JNJ.N sold it.

Cordis is known for making cardiovascular devices such as catheters and stents.

H&F and KKR KKR.N, an investor in Cordis, declined to comment. Cordis did not immediately respond to Reuters' requests for comment outside of regular business hours.

(Reporting by Carlos Méndez in Mexico City, editing by Chris Reese)

((Carlos.Mendez@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2604917204?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-17 08:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2604917204","market":"fut","top_or_hot":-1,"title":"H&F weighs $9 billion-plus sale of medical device maker Cordis, Bloomberg News reports","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>UPDATE 2-H&amp;F weighs $9 billion-plus sale of medical device maker Cordis, Bloomberg News reports</title></head><body><p>Updates with KKR comments in the last paragraph</p><p><span>Jan 16 (Reuters)</span><span> - </span>U.S. private equity firm Hellman &amp; Friedman is in early-stage talks for a potential sale of medical devices maker Cordis, seeking a value of over $9 billion, Bloomberg News reported on Friday, citing people familiar with the matter.</p><p>About half a dozen publicly traded medical device companies are currently evaluating potential bids for Cordis, the report added.</p><p>Hellman &amp; Friedman bought Cordis from Cardinal <a href=\"https://laohu8.com/S/HIT\">Health in</a> 2021 for about $1 billion, six years after Johnson &amp; Johnson <span><a href=\"https://laohu8.com/S/JNJ\">JNJ</a>.N</span> sold it.</p><p>Cordis is known for making cardiovascular devices such as catheters and stents.</p><p>H&amp;F and KKR <span>KKR.N</span>, an investor in Cordis, declined to comment. Cordis did not immediately respond to Reuters' requests for comment outside of regular business hours.</p><p> (Reporting by Carlos Méndez in Mexico City, editing by Chris Reese)</p><p> ((Carlos.Mendez@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>H&F weighs $9 billion-plus sale of medical device maker Cordis, Bloomberg News reports</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nH&F weighs $9 billion-plus sale of medical device maker Cordis, Bloomberg News reports\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-17 08:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>UPDATE 2-H&amp;F weighs $9 billion-plus sale of medical device maker Cordis, Bloomberg News reports</title></head><body><p>Updates with KKR comments in the last paragraph</p><p><span>Jan 16 (Reuters)</span><span> - </span>U.S. private equity firm Hellman &amp; Friedman is in early-stage talks for a potential sale of medical devices maker Cordis, seeking a value of over $9 billion, Bloomberg News reported on Friday, citing people familiar with the matter.</p><p>About half a dozen publicly traded medical device companies are currently evaluating potential bids for Cordis, the report added.</p><p>Hellman &amp; Friedman bought Cordis from Cardinal <a href=\"https://laohu8.com/S/HIT\">Health in</a> 2021 for about $1 billion, six years after Johnson &amp; Johnson <span><a href=\"https://laohu8.com/S/JNJ\">JNJ</a>.N</span> sold it.</p><p>Cordis is known for making cardiovascular devices such as catheters and stents.</p><p>H&amp;F and KKR <span>KKR.N</span>, an investor in Cordis, declined to comment. Cordis did not immediately respond to Reuters' requests for comment outside of regular business hours.</p><p> (Reporting by Carlos Méndez in Mexico City, editing by Chris Reese)</p><p> ((Carlos.Mendez@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2505996681.GBP","symbol_name":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4H\" (GBPHDG) INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260117:nL6N3YI002:1","article_id":"2604917204","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2604917204","pubTimestamp":1768610123,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"UPDATE 2-H&F weighs $9 billion-plus sale of medical device maker Cordis, Bloomberg News reportsUpdates with KKR comments in the last paragraphJan 16  - U.S. private equity firm Hellman & Friedman is in early-stage talks for a potential sale of medical devices maker Cordis, seeking a value of over $9 billion, Bloomberg News reported on Friday, citing people familiar with the matter.About half a dozen publicly traded medical device companies are currently evaluating potential bids for Cordis, the report added.Hellman & Friedman bought Cordis from Cardinal Health in 2021 for about $1 billion, six years after Johnson & Johnson JNJ.N sold it.Cordis is known for making cardiovascular devices such as catheters and stents.H&F and KKR KKR.N, an investor in Cordis, declined to comment. Cordis did not immediately respond to Reuters' requests for comment outside of regular business hours.  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2505996681.GBP":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4H\" (GBPHDG) INC","LU0683600562.USD":"AB SELECT US EQUITY \"A\" (USD) ACC","LU0889566641.SGD":"FTSF - Templeton Shariah Global Equity A Acc SGD","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","IE00BVYPNV92.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) ACC","LU0234570918.USD":"高盛全球核心股票组合Acc Close","IE00BGHQF631.EUR":"GUINNESS GLOBAL EQUITY INCOME \"C\" (EUR) ACC","BK4532":"文艺复兴科技持仓","BK4581":"高盛持仓","LU1506573853.SGD":"MANULIFE GF GLOBAL EQUITY \"AA\" (SGD) INC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","IE0034235303.USD":"PINEBRIDGE US RESEARCH ENHANCED CORE EQUITY \"A\" (USD) ACC","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","IE00BN8TJ469.HKD":"FTGF CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A\" (HKD) INC","LU0795875086.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD","LU2471134879.HKD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (HKD) INC","LU0689626769.HKD":"AB SICAV I - SUSTAINABLE US THEMATIC PORTFOLIO \"A\" (HKD) ACC","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","LU2471134523.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU2129689514.USD":"FRANKLIN GLOBAL INCOME \"A\" (USD) INC","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","LU0345769128.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) ACC","LU1221951046.USD":"NORDEA 1 STABLE RETURN \"HM\" (USDHDG) INC","LU1935042991.SGD":"MANULIFE GF GLOBAL MULTI-ASSET DIVERSIFIED INCOME  \"AA\" (SGDHDG) INC","LU0122379950.USD":"贝莱德世界健康科学A2","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU2129689431.USD":"FRANKLIN GLOBAL INCOME \"A\" (USD) ACC","LU2592432038.USD":"WELLINGTON MULTI-ASSET HIGH INCOME \"A\" (USD) ACC","LU2430703095.HKD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4\" (HKD) INC","LU0345769631.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) INC","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","BK4592":"伊斯兰概念","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","JNJ":"强生","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","IE00BVYPNW00.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) ACC","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU2602419157.SGD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","BK4568":"美国抗疫概念","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU1732800096.USD":"摩根大通环球收益基金A (irc)","LU0124676726.USD":"AB SICAV I - SUSTAINABLE US THEMATIC PORTFOLIO \"A\" (USD) ACC","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LU1066051225.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AC\" (USD) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1496350502.SGD":"FRANKLIN DIVERSIFIED DYNAMIC \"A\" (SGDHDG) ACC"},"translate_title":"据彭博社报道，H&F斥资超过90亿美元出售医疗设备制造商Cordis","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JNJ":0.9},"content_text":"UPDATE 2-H&F weighs $9 billion-plus sale of medical device maker Cordis, Bloomberg News reportsUpdates with KKR comments in the last paragraphJan 16 (Reuters) - U.S. private equity firm Hellman & Friedman is in early-stage talks for a potential sale of medical devices maker Cordis, seeking a value of over $9 billion, Bloomberg News reported on Friday, citing people familiar with the matter.About half a dozen publicly traded medical device companies are currently evaluating potential bids for Cordis, the report added.Hellman & Friedman bought Cordis from Cardinal Health in 2021 for about $1 billion, six years after Johnson & Johnson JNJ.N sold it.Cordis is known for making cardiovascular devices such as catheters and stents.H&F and KKR KKR.N, an investor in Cordis, declined to comment. Cordis did not immediately respond to Reuters' requests for comment outside of regular business hours. (Reporting by Carlos Méndez in Mexico City, editing by Chris Reese) ((Carlos.Mendez@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"event","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2604917204","isCrawlerRequest":true}